P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease

TransfusionVolume 63, Issue S5 p. 159A-160A SUPPLEMENT ARTICLE P-CB-21 | RBC Alloimmunization Responder Type and COVID-19 Vaccine IgG Response in Patients with Sickle Cell Disease H. Nakahara, H. Nakahara Emory University School of MedicineSearch for more papers by this authorN. Cheedarla, N. Cheedarla Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorH. Verkerke, H. Verkerke Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorS. Cheedarla, S. Cheedarla Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorS. Wu, S. Wu Brigham and Womens’ Hospital, Harvard UniversitySearch for more papers by this authorJ. Hendrickson, J. Hendrickson Emory University School of MedicineSearch for more papers by this authorJ. Roback, J. Roback Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorA. Neish, A. Neish Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorR. Fasano, R. Fasano Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USASearch for more papers by this authorS. Stowell, S. Stowell Brigham and Womens’ Hospital, Harvard UniversitySearch for more papers by this author H. Nakahara, H. Nakahara Emory University School of MedicineSearch for more papers by this authorN. Cheedarla, N. Cheedarla Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorH. Verkerke, H. Verkerke Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorS. Cheedarla, S. Cheedarla Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorS. Wu, S. Wu Brigham and Womens’ Hospital, Harvard UniversitySearch for more papers by this authorJ. Hendrickson, J. Hendrickson Emory University School of MedicineSearch for more papers by this authorJ. Roback, J. Roback Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorA. Neish, A. Neish Department of Pathology and Laboratory Medicine, Emory University School of MedicineSearch for more papers by this authorR. Fasano, R. Fasano Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USASearch for more papers by this authorS. Stowell, S. Stowell Brigham and Womens’ Hospital, Harvard UniversitySearch for more papers by this author First published: 12 October 2023 https://doi.org/10.1111/trf.204_17554Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume63, IssueS5October 2023Pages 159A-160A RelatedInformation